Navigation Links
WebMD Completes Redemption of 3 1/8% Convertible Notes
Date:12/30/2010

NEW YORK, Dec. 30, 2010 /PRNewswire-FirstCall/ -- WebMD Health Corp. (Nasdaq: WBMD) has completed the optional redemption of its 3 1/8% Convertible Notes due 2025.  When the redemption was announced earlier in December, approximately $84.8 million in aggregate principal amount of the 3 1/8% Notes were outstanding.  In lieu of cash redemption, holders of substantially all of those 3 1/8% Notes converted their holdings into approximately 2.4 million shares of WebMD common stock.  The remaining $50 thousand principal amount of the 3 1/8% Notes were redeemed for 100.893% of the principal amount plus accrued interest.  As a result, WebMD no longer has any of the 3 1/8% Notes outstanding.  WebMD expects to take a non-cash pre-tax charge of approximately $7 million during the quarter ending December 31, 2010 related to the conversions and redemptions of the 3 1/8% Notes.

As of December 29, 2010, WebMD had approximately 59.9 million shares of its common stock outstanding, including the shares issued upon conversion of the 3 1/8% Notes and excluding approximately 1.1 million shares of unvested restricted stock.

About WebMD

WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through our public and private online portals and health-focused publications. More than 80 million unique visitors access the WebMD Health Network each month.

The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, eMedicine, eMedicine Health, RxList, theHeart.org and drugs.com.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements. These statements are based on WebMD's current plans and expectations and involve risks and uncertainties, including those described in our SEC filings.


'/>"/>
SOURCE WebMD
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders
2. WebMD Launches New Consumer Health Portal in the U.K.
3. WebMD Health Corp. Announces Intention To Commence Tender Offer To Repurchase Up To 5,700,000 Shares of its Common Stock
4. WebMD to Present at the 2009 Citi Investment Research Small and Mid Cap Conference
5. WebMD Announces 2009 Health Heroes
6. WebMD to Present at the Citi 7th Annual U.S. Small/Mid Cap Conference
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans and ... that we all are aware of our options and are empowered with strength ... the launch of its newest edition of "Vision and Hearing" in USA Today, ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... Yisrayl ... that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding ... this current generation. He explains that the Bible details the current times so ...
(Date:2/24/2017)... Emeryville, CA (PRWEB) , ... February 24, 2017 ... ... Esparza for qualifying into the Senior International Elite division on February 12th. ... All Around divisions at the elite qualifier competition held in Las Vegas, Nevada. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
Breaking Medicine News(10 mins):